Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Importance: Clinical trials of dupilumab for atopic dermatitis (AD) have reported an increased incidence of conjunctivitis in patients who received dupilumab compared with those who received placebo. Objective: To describe the characteristics of patients who develop conjunctivitis secondary to dupilumab treatment for AD. Design, Setting, and Participants: Case series of 12 patients who reported development of conjunctivitis from a cohort of 142 patients treated with dupilumab for AD at a secondary care center from March 14, 2017, to March 29, 2018. Exposures: Patients received a 600-mg injection of dupilumab as a loading dose and a 300-mg injection every 2 weeks thereafter. Main Outcomes and Measures: Primary outcome measures were severity of AD as measured by the Investigator Global Assessment (IGA) score, a 5-point scale from 0 (clear) to 4 (severe), at the time of dupilumab initiation and at conjunctivitis onset. Results: Of the 12 patients included in this series, 7 (58%) were male. The mean (SD) age of patients was 30 (8.1) years at the time conjunctivitis developed. All patients showed improvement of their AD at the time of conjunctivitis diagnosis, with a mean (SD) 1.9 (0.8)-point decrease in IGA score and 47.8% (11.2%) decrease in body surface area affected. Nine of the 12 patients (75%) had severe baseline AD with an IGA score of 4. All patients who discontinued treatment had severe AD at the time of initial dupilumab administration and had at least 1 atopic condition in addition to AD. Conclusions and Relevance: Conjunctivitis that develops after administration of dupilumab to treat AD may be severe enough to necessitate stopping therapy. Severe conjunctivitis was more likely to develop in patients with more severe baseline AD who had a good response to dupilumab and an increased atopic phenotype. Studies are needed to confirm risk factors associated with development of conjunctivitis and to determine effective treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Cited by
Conjunctivitis in dupilumab clinical trials
Akinlade, B., Guttman‐Yassky, E., Bruin‐Weller, M., Simpson, E. L., Blauvelt, A., Cork, M. J., Prens, E., Asbell, P., Akpek, E., Corren, J., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17869 · Cited by 442
Guttman-Yassky, E., Blauvelt, A., Eichenfield, L. F., Paller, A. S., Armstrong, A. W., Drew, J., Gopalan, R., & Simpson, E. L. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.0079 · Cited by 341
Faiz, S., Giovannelli, J., Podevin, C., Jachiet, M., Bouaziz, J.-D., Reguiai, Z., Nosbaum, A., Lasek, A., Ferrier le Bouedec, M.-C., Du Thanh, A., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.02.053 · Cited by 210
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
Bansal, A., Simpson, E. L., Paller, A. S., Siegfried, E. C., Blauvelt, A., de Bruin-Weller, M., Corren, J., Sher, L., Guttman-Yassky, E., Chen, Z., et al. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00577-1 · Cited by 52
Shi, V. Y., Chamberlain, W., Siegfried, E., Kraff-Cooper, C., Beckman, K., Lio, P., Paller, A. S., & Simpson, E. (2023) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.01.043 · Cited by 18
“10 Evaluation of conjunc-tivitis and treatment of conjunctivitis associated with AD biologics have been recently reviewed.”
Self-citation
Metadata
- Authors
- Treister, A. D., Kraff-Cooper, C., & Lio, P. A.
- Venue
- JAMA Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-10-01
- Volume
- 154
- Issue
- 10
- Pages
- 1208
- ISSN
- 2168-6068 (ISSN-L)
- OpenAlex
- W2888908499
- Cited by
- 135
- References
- 1
- FWCI
- 17.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis. https://app.cochat.ai/papers/10.1001/jamadermatol.2018.2690
- The paper
- Treister, A. D., Kraff-Cooper, C., & Lio, P. A. (2018). Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2018.2690
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.